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1.  INTRODUCTION 
 Thyroid cancer is the most common endocrine malignancy, among which   
95% of them  originate from the thyroid follicular epithelial cells (1). Worldwide, 
the incidence of thyroid cancer is roughly three to four times higher among 
women than men and it is ranked the sixth most common malignancy diagnosed 
in women(2). Most of the tumors are common between the third to the sixth decade 
of life and they are rare in childhood(2) . Follicular adenoma and Follicular 
carcinoma of thyroid are the tumors of epithelial origin with follicular cell 
differentiation. Of them, the incidence of follicular adenoma was  3% and 4.3%   
as reported in two autopsy series(3,4) . Follicular Thyroid Cancer (FTC) is reported 
to be the second most common malignancy of the thyroid gland after Papillary 
Thyroid Carcinoma (PTC). Follicular neoplasm of the thyroid is  classified into 
benign and malignant depending on the presence or absence of capsular and/or 
vascular permeation. However, evaluation of these features  in histopathology is 
challenging, as the presence of an incomplete capsular invasion or equivocal 
vascular invasion due to processing or sectioning artefacts results in an 
inconclusive or inaccurate diagnosis(5).Distinguishing  Follicular thyroid 
carcinoma(FTC) especially Minimally Invasive Follicular Carcinoma (MIFC) of 
thyroid from the most common neoplasm of the thyroid, follicular thyroid 
adenoma  is very challenging, leading to avoidable surgery and exposing   the 
patients to persuasive  postoperative complications. Hence the question arises- Is 
histomorphology, the gold standard in the diagnosis of follicular thyroid lesions? 
This study aims at addressing the challenges regarding the diagnosis of follicular 
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thyroid neoplasm. Recent studies have focused on identifying 
immunohistochemical markers that may help in differentiating benign from  
malignant follicular thyroid tumors(6).Estimation of the expression of CD56 and 
GALECTIN 3 may help to differentiate between malignant and benign follicular 
thyroid neoplasm.  
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2. AIMS AND OBJECTIVES 
 
1. To study the expression of immunohistochemical markers CD56 and 
GALECTIN 3 in benign and malignant follicular tumors of thyroid. 
2. To assess the significance of expression of these markers in follicular 
neoplasm of thyroid. 
3. To ascertain the usefulness of these markers for diagnostic purpose. 
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3. REVIEW OF LITERATURE 
 
3.1)  Anatomy of Thyroid Gland 
 
Figure -1 ; Adapted from- Lloyd RV Douglas, BR, Young FW editors. 
Endocrine diseases. Washington, DC; AFIP Atlas of Nontumor Pathology; 
2001; 
 
 The thyroid gland is a bilobated organ weighing from 15 to 25 g, which is 
located in the neck in front of the larynx and trachea. The two lobes are connected 
by the isthmus. The gland is surrounded by a thin fibrous capsule and it is divided 
into lobules. The parathyroid glands are situated posterior to the thyroid and next 
to the recurrent laryngeal nerves, which run between the trachea and  
oesophagus(7) The superior thyroid arteries, which branch from the external 
carotid arteries, and the inferior thyroid arteries, which branch from the 
subclavian arteries supply the thyroid gland. The superior and middle cervical 
sympathetic ganglia form the nerve supply of thyroid(8–10) 
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                     During embryogenesis, the thyroid gland arises from the foramen 
caecum of the tongue as an endodermal structure.It descends as a part of the 
thyroglossal duct, which usually atrophies, but remnants may be found in adults 
along this duct, such as in the ovaries (struma ovarii).(8–10The  internal jugular 
lymph nodes are drained by  intraglandular and subcapsular  lymphatics.(11,12) 
 
3.2)   Histology of thyroid 
         
Figure -2; Adapted from -   Bruce M Wenig . Atlas of Head and Neck 
Pathology.   Elsevier  Health Sciences; 2015. 1803 p. 
- Section of a thyroid gland shows colloid filled follicles lined by endothelial 
cells, (H &E stain, under 40 x). 
                                                                                      
 Ultrastructural studies of normal thyroid gland  show that the follicular 
cells  are variable in size, with an average diameter of 200 µm and they  are 
arranged in a single layer around the central colloid (11) . Their nuclei are round 
containing  diffuse chromatin.  Colloid  contains concentrated periodic acid-Schiff 
(PAS)-positive thyroglobulin.(12) . 
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3.3)  Physiology and functions of thyroid 
                      The thyroid gland is a part of the hypothalamus-pituitary- 
axis(HPA).A feedback system activating from the hypothalamus, producing  
Thyrotrophic Releasing Hormone( TRH)  and activates the thyrotrophic cells in 
the anterior lobe of the pituitary gland to release( TSH) Thyrotrophic Secreting 
Hormone  activates the thyroid follicular cells  to produce thyroid hormones 
called triiodothyroxine (T3) and tetraiodothyronine or thyroxine (T4). As a 
negative feedback mechanism, the hormones (T3 and T4) control the secretion of 
both TSH and TRH. The thyroid hormones have numerous activities in body 
metabolism, such as oxygen consumption, cardiac output and heat production. (13) 
3.4)   Histochemistry of thyroid 
 Immunohistochemically, many markers have been documented in normal 
follicular  cells, most of them are also being also expressed in well-differentiated 
tumors cells: 
•  
• Reactivity for thyroglobulin, thyroid peroxidase, triiodothyronine (T3), 
and thyroxine (T4) has been found both in the colloid and in the 
cytoplasm of the  follicular cells.(14–16)  Thyroglobulin is the most widely  
used of all  these markers.(16)  
•  
• Thyroid transcription factor 1 (TTF-1) has developed  as an extremely 
useful marker for thyroid origin  and tumors composed of  thyroid 
follicular cells.(17) The only other tissue that showed consistent 
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expression was the alveolar epithelium of the lung.(18) However, reports 
have recently appeared documenting its occasional presence in other 
sites, such as the normal and neoplastic  female genital tract,(19,20) Wilms 
tumor,(21) and Merkel cell tumor.(22) 
•  
• Low molecular weight keratins: CK7, CK18, and (to a lesser degree) 
CK8 and CK19.(23) 
•  • Epithelial membrane antigen (EMA). 
•  • Vimentin.(23) 
•  • Estrogen and progesterone receptors.(24) 
•  • Blood group antigens.(25) 
•  
• Low  molecular metal binding proteins such as ceruloplasmin, 
lactoferrin, transferrin, metallothionein.(26,27) 
•  
• Follicular cells are joined by tight junctions containing the known 
components of these structures, including occludin and the various 
claudins.(28) 
•  
• The follicles rest on a basement membrane that is immunoreactive for 
laminin and type IV collagen.(29) 
 
o The second type of hormone-producing cell are the C cells,  which accounts 
for only 0.1% of the thyroid mass. They may be found as small clusters in the 
middle to upper third of the lateral lobes, usually in an intrafollicular position. 
The C cells produce calcitonin, somatostatin and other peptides. 
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Immunohistochemically, they accumulate calcitonin, TTF-1, somatostatin and 
neuroendocrine markers, such as chromogranin A and synaptophysin.  
o The third cell type of the normal thyroid gland  are Solid cell nests, from 
which  C cells are derived.  
3.5)  Neoplasm of thyroid 
 Numerous pathologic lesions affect thyroid gland with diverse 
morphologies. Despite the large number of lesions, it is convenient to divide them  
into two major types: one that shows a diffuse pattern and the other  that produce 
nodules. Diffuse thyroid lesions are the lesions in which entire thyroid gland is  
affected, such as hyperplasias and thyroiditis. Nodular lesions  are those ,which  
include both  non neoplastic hyperplasias  as well as benign and malignant 
tumors(30). The thyroid tumors are of two major types; one is that arises from 
thyroid follicular cells such as   papillary carcinoma of thyroid , follicular  
carcinoma of thyroid  and anaplastic  carcinoma of thyroid. Other is Medullary 
carcinoma of  thyroid that  arises from thyroid  parafollicular C  cells(2).  
 The majority of the thyroid tumors can be promptly diagnosed by 
characteristic histopathological features, but the distinction between follicular 
adenomas and follicular carcinomas are troublesome.   Follicular thyroid tumors 
were categorised into benign or malignant depending upon the presence or 
absence of capsular and/or vascular invasion.  On the other hand, assessment of 
these features can be  very challenging due to the presence of incomplete capsular 
penetration or equivocal vascular permeation .This  may be due to  processing and 
sectioning artifacts. Atypical follicular adenoma with increased cellularity and 
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nuclear atypia are very difficult to differentiate from minimally invasive follicular 
carcinoma of thyroid.  As some promising immunohistochemical markers  
including CD56,  galectin 3 ,Hector Battifora Mesothelial (HBME-1), and CK19  
may  distinguish  benign from malignant  follicular thyroid tumors .(31)  
3.6 )   WHO  classification of thyroid tumors - (2017)(32) 
1. Tumors of the thyroid gland 
a. Follicular adenoma 
b. Hyalinizing trabecular tumor 
c. Other encapsulated follicular patterned thyroid tumors 
i. Tumors of  uncertain malignant potential 
ii. Noninvasive  follicular thyroid neoplasm with papillary-like 
nuclear features 
d. Papillary thyroid carcinoma 
e. Follicular thyroid carcinoma 
i. Hürthle (oncocytic) cell tumors 
f. Poorly differentiated thyroid carcinoma 
g. Anaplastic thyroid carcinoma 
h. Squamous cell carcinoma 
i. Medullary thyroid carcinoma 
j. Mixed medullary and follicular thyroid carcinoma 
k. Mucoepidermoid carcinoma 
l. Sclerosing mucoepidermoid carcinoma with eosinophilia 
m. Mucinous carcinoma 
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n. Ectopic thymoma 
o. Spindle epithelial tumor with thymus-like differentiation 
p. Intrathyroid thymic carcinoma 
q. Paraganglioma and mesenchymal / stromal tumors 
i. Paraganglioma 
ii. Peripheral nerve sheath tumors 
iii. Benign vascular tumors 
iv. Angiosarcoma 
v. Smooth muscle tumors 
vi. Solitary fibrous tumor 
r. Hematolymphoid tumors 
i. Langerhans cell histiocytosis 
ii. Rosai-Dorfman disease 
iii. Follicular dendritic cell sarcoma 
iv. Primary thyroid lymphoma 
s. Germ cell tumors 
t. Secondary tumors 
3.7)  Benign follicular thyroid tumors 
 3.7.1   Follicular thyroid adenoma 
 Follicular adenoma is a benign encapsulated tumor with  follicular 
epithelial cell differentiation. it  is the most common neoplasm of the thyroid, 
with a evident of  15−20% proportion among thyroid nodules (33,34). Follicuar 
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adenoma lacks: (i)  the evidence of capsular, vascular or any other type of 
invasion; and (ii) the nuclear features of the papillary family of neoplasms. 
 
a) Clinical presentation 
 Follicular  adenomas are five-fold more common in females than in males 
with a wide age range ,but most common in the 5th-6th decades of life(35).  
Adenomas are mainly nonfunctional. A small proportion shows autonomous 
hyperfunction (toxic adenoma), causing thyrotoxicosis. Tumors are usually found 
by palpation and may sometimes cause pressure effects, such as dysphagia and 
dyspnoea.(35)  
b) Etiology 
 Radiation, iodine deficiency and history of nodular goiter are the major risk 
factors for follicular thyroid neoplasia (35) Some genetic alterations are shown in  
toxic adenomas, such as mutations in RAS, phosphotidylinositol 3-kinase, 
catalytic alpha polypeptide (PI3KCA) and TSH receptor gene (35). 
c) Features of  Fine Needle Aspiration Biopsy:(36) 
 Features  of a follicular neoplasm (38)in contrast to an  adenomatoid nodule   
are that, they have moderate to high  cellularity, arranged in syncytial groups with  
prominent  micro follicular pattern of clusters that may contain  a drop of  colloid. 
The cells are uniform , forming repetitive micro follicles with round nuclei . The  
nuclear chromatin  may be   coarsely granular, and it  is usually evenly distributed 
with inconspicuous nucleoli. Absence of nuclear  features for papillary thyroid 
carcinoma. 
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d) Macroscopic appearance of follicular adenoma; 
 Follicular  thyroid  adenoma  is  almost  solitary  and  confined  to one lobe 
of thyroid .Macroscopically, an adenoma is surrounded by a well-demarcated and 
intact capsule, the capsule varies in thickness but usually it is thin. If a thick 
capsule is present, suspicion of   carcinoma should be thought of.(37).Adenomas 
vary in size but generally measure < 3 cm. Larger tumors measuring more than 10 
cm can  also be seen.  Follicular adenomas are usually  nodular   with firm 
consistency, tan to light brown in color. (9,10)  (except in the presence of secondary 
[degenerative] changes); Secondary changes include hemorrhage, fibrosis, cyst 
formation, calcification. 
e)  Microscopic  appearance of follicular adenoma; 
 Microscopically, in follicular adenoma the  cells are  arranged in a normo   
follicular(simple), macro follicular (colloid), micro follicular (fetal), and 
trabecular /solid (embryonal) pattern with uniform nuclear and cellular 
morphology and with rare mitotic cells.  
f) Follicular  Thyroid Adenoma  -Histologic Types; 
 Oncocytic (Hürthle) cell 
  Signet ring cell  
  Clear cell 
  Follicular adenoma with:  
 spindle cells  
 mucinous stroma  
 mesenchymal components               
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 Hyalinizing  Trabecular  Adenoma 
 Atypical  Follicular  Adenoma. 
  
Other  rare type  of follicular adenoma are those 
o with clear cell changes ( the signet ring, mucin-producing, and lipid-rich 
types); 
o with adipose metaplasia of the stroma (so-called adenolipomas)(38), 
o with cartilaginous metaplasia (so-called adenochonromas),(39)  
o spindle cell adenomas (some vaguely resembling meningiomas),(40)  
o with massive deposition of cytoplasmic black pigment following 
minocycline therapy (so-called black adenomas).(41). 
f)   Differential  diagnosis of follicular adenoma; 
 The differential  diagnosis of  follicular thyroid  adenoma  are   dominant  
nodule of nodular hyperplasia, follicular  thyroid carcinoma with minimal 
invasion, and the follicular variant of papillary  thyroid carcinoma. Some 
follicular adenomas are highly vascular so this may be  confused with vascular 
tumors. Atypical follicular adenoma  which have high cellularity and  atypical 
nuclei  may  also difficult to diagnose.  
3.7.2  Atypical follicular adenoma 
Synonyms: Atypical follicular neoplasm; follicular tumor of uncertain malignant 
potential(FT-UMP); well- differentiated (follicular) tumor of uncertain malignant 
potential(WDT-UMP) 
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Figure -3 ; Adapted from- Bruce M Wenig. Atlas of Head and Neck 
Pathology. Elsevier Health Sciences; 2015. 
- Section shows focal areas of bizarre hyper chromatic and pleomorphic nuclei  
lacking the features of malignancy such as mitosis and necrosis. 
 
 Atypical  follicular adenoma  is diagnosed, when  any encapsulated 
follicular tumors have  histological  features  suggestive of a more aggressive 
neoplasm, but does not show any evidence of either capsular or vascular 
invasion.(42) Atypical histological  features include thickened capsule, unusual 
cellularity  particularly along the peripheral   aspects of the tumor that is  along 
the tumor-capsular  interface, increased  mitoses, and  atypical  with    prominent 
nucleoli ,  spontaneous necrosis and  infarction . Follow‐up studies  have shown  
that  atypical follicular adenoma  behave  like  benign tumors(43–45). Such tumors 
represent  a “grey zone” and  termed   as follicular tumors of uncertain malignant 
potential. Immunohistochemistry  using CD56 helps in distinguishing benign 
(particularly atypical  follicular  thyroid adenoma) from  malignant tumors(31) .  
p27 is other  reliable marker that may distinguish atypical  follicular adenoma  
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from follicular  thyroid carcinoma .GALECTIN 3 is a most sensitive marker in 
differentiating Follicular adenoma  of thyroid  from  Follicular carcinoma of 
thyroid . 
3.7.3 Hyalinising Trabecular Adenoma (HTA) 
             Benign encapsulated tumor with evidence of follicular epithelial cell 
differentiation showing trabecular and organoid growth patterns. Hyalinising 
Trabecular Adenoma (HTA) have  extracellular hyalinization and elongated cells 
arranged around blood vessels. The pattern of growth may simulate  
paraganglioma and medullary carcinoma of thyroid .The presence of nuclear 
grooves and psammoma bodies may suggest papillary carcinoma, particularly in 
material from fine needle aspiration.(46) Another distinct morphologic feature of 
HTA is the so-called cytoplasmic yellow body, which is a round, pale yellow 
cytoplasmic inclusion body in a paranuclear location having a refractile quality 
and detectable both in tissue sections and in fine needle aspiration smears.(47,48). 
Immunohistochemically hyalinising trabecular adenoma shows consistent 
positivity for Cytokeratins, thyroglobulin,  and TTF-1. It shows  reactivity  for  
Galectin 3in about half of the cases (49) and focal  inconstant reactivity for 
neuroendocrine markers such as NSE and neurotensin.(50). HBME-1 is consistently 
negative in hyalinising trabecular adenoma. (51)  
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Figure -4; Adapted from - Carney JA. Hyalinizing trabecular tumors of the 
thyroid gland:. Am J Surg Pathol. 2008 Apr;32(4):622–34. 
- Section  shows elongated cells that may be oriented perpendicular to fibro 
vascular cores with oval and elongated nuclei ,fine dispersed chromatin and 
nuclear grooves. 
 
3.8)  Malignant follicular thyroid tumors 
3.8.1 Follicular Thyroid Carcinoma  (FTC) 
a) Definition; 
 Follicular cell differentiated  thyroid neoplasm, have  the  evidence  of  
capsular and/or vascular invasion) and/or metastatic disease and it  does not have 
the nuclear features of papillary thyroid carcinoma.  
a) Epidemiology of thyroid cancer; 
 The National Cancer Institute reports that thyroid  cancer   is the most 
common endocrine malignancy ,with incidence of  64,330 new cases in 2016. 
Thyroid cancer constitutes  approximately 3.8% of all new cancer cases (52). 
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Papillary carcinoma of  thyroid  comprises  85-90% of all thyroid cancer cases, 
followed by  follicular thyroid carcinoma of  (5-10% ) and medullary thyroid 
Cancer (about 2%), anaplastic thyroid  carcinoma  accounts  for  less than 2% of 
thyroid cancers(53). 
 The second most common malignancy of thyroid is  Follicular  carcinoma  
of  thyroid  (54,55) . The reported  incidence of Follicular Thyroid Carcinoma ranges  
from 10% to 32% of  all  differentiated  thyroid carcinomas (56). .This  wide range 
in the   reported incidence could be due to an inter observer variability in the histo   
pathological diagnosis of follicular carcinoma of thyroid .(56) 
 According to the previous  studies the incidence of  follicular carcinoma of 
thyroid has been decreased recently. (57,58). This decrease in incidence may be due 
to more liberal approach in the histopathological  diagnosis (e.g. diagnosis  of 
follicular variant of papillary carcinoma of  thyroid) and  iodine  supplementation 
programs. A 5-year survival of follicular thyroid cancer  patients is approximately 
85−95% .(59) 
 c) Tumor genesis of  follicular carcinoma; 
 The incidence of Follicular thyroid  carcinoma is higher in  endemic areas  
of  iodine deficiency, because addition of iodine supplement to the diet has been 
associated with a decline in the incidence of follicular thyroid  carcinoma in  
geographic areas(60). Rarely, follicular thyroid carcinoma may occur from a pre-
existing follicular adenoma.(61) Dyshormonogenesis and irradiation may leads to 
the development of follicular carcinoma of thyroid. 
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d) Cytogenetic and molecular features of Follicular Thyroid Carcinoma; 
 Activating  point  mutations of  RAS gene occur in 20% to 40% of 
follicular adenomas and 30%to 50% of follicular carcinomas, suggesting   that  
RAS mutation may  represent  an early event in tumor genesis . PAX8-PPARγ  
gene  fusion -  results in  the  production of  fusion protein (PPFP) .PPFP is an 
oncoprotein and it is seen in  follicular thyroid adenoma  and carcinoma and  
papillary  thyroid  carcinomas- Follicular Variant , but not in conventional 
papillary  thyroid carcinomas (62). 
                    Genetic cancer susceptibility is more common among endocrine tumors 
than any other human  tumors.(63) 6% of Familial Non Medullary Thyroid Cancers 
(FNMTCs) are believed to be Familial Follicular Thyroid Cancers (FFTCs), may 
be associated with syndromes such as Cowden or Werner syndromes or the 
Carney complex(64). 
               Phosphatase  Tensin  (PTEN) tumor  suppressor gene   mutation  causes  
Cowden syndrome with   greater  susceptibility  of  breast, endometrial, thyroid, 
kidney and colorectal cancers, including dermatological , gastrointestinal and 
neurological features. Up to 10% of patients with Cowden syndrome develops 
thyroid cancer, usually a follicuar thyroid carcinoma.(65)  
                         Werner syndrome  which is also known as adult progeria, caused 
by the  mutations   in  Werner syndrome, RecQ helicaselike (WRN) gene, causing  
premature aging of  patients and  related  with an increased risk of carcinoma  
including follicular carcinoma of  thyroid(66). The Carney complex is  caused by  
the mutation  in Protein kinase, cyclic Adenosine Mono Phosphate (cAMP)-
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dependent, Regulatory, type 1,Aalpha (PRKAR1A) gene  leads to the tumors  in 
the heart, skin, endocrine organs such as the thyroid, and pigmentations of the 
skin .(13). 
e) Clinical presentation of  Follicular Thyroid Carcinoma(FTC); 
 Follicular thyroid carcinoma presents as an asymptomatic slowly growing 
solitary mass (usually measuring >2 cm) in the thyroid(67). Pain may occur later in 
the disease course. The most important  criteria for the diagnosis of follicular 
thyroid  carcinoma is  the  demonstration of capsular invasion  and/or vascular 
invasion. Therefore histological   examination of  the tumor- capsule interface is 
more important than examination of central portion of the tumor. Follicular 
carcinoma spreads hematogenously and characteristically metastases to bone, 
lung, brain and liver(68). Follicular carcinoma of thyroid  do not invade lymphatics.  
Oxyphilic variant  of  follicular carcinoma typically recurs in the neck and 
metastasizes more  than the conventional type .(59)  
f) Features of Fine Needle Aspiration Biopsy (FNAB) ; 
 In the diagnosis of follicular carcinoma of thyroid   the use of  Fine Needle 
Aspiration Biopsy is limited ,because  it cannot provide    the details about capsule 
and/ or vascular invasion. Cytological features in follicular adenoma and follicular 
carcinoma are similar  with cellular smears composed of syncytial clusters of 
crowded cells  and   repetitive follicles with lumen having  scant colloid. The cells 
are monomorphic  and   larger  than  non-neoplastic follicular epithelial cells. 
Nuclei  is uniformly enlarged with inconspicuous nucleoli  and shows nuclear 
overlapping. 
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g) Macroscopic appearance of Follicular Thyroid Carcinoma; 
 Follicular thyroid carcinoma  are typically round or oval in shape  and have 
thick capsule. Macroscopically, the tumors are light brown to pink in cut section, 
with  areas of haemorrhage, necrosis and fibrosis.(13). Kuru et al (69) found that nod-
ule size ≥4 cm was associated with increased risk of malignancy compared with 
nodule size <4 cm. 
e) Microscopic appearance of  Follicular Thyroid Carcinoma; 
 Microscopically, these  carcinomas are  quite uniform and  hyper cellular, 
showing  follicle formation with minimal  colloid, while a widely invasive 
subtype often shows  a solid or trabecular  growth pattern. The  tumor cells lack 
the nuclear features of  papillary carcinoma of thyroid.The hurtle cell variant of 
follicular thyroid carcinoma  is composed of oxyphilic cells with a typical 
appearance of abundant granular and eosinophilic cytoplasm filled with swollen 
mitochondria with scant or absent colloid. Clear cell change may be prominent in 
oncocytic neoplasia .(63) 
 The  presence of   vascular and/or capsular invasion is the  only feature that   
can distinguishes a follicular  carcinoma  from  follicular  adenoma, which means 
that  distinction between the two requires thorough  inspection of the tumor-
capsule interface.(70) 
i) Follicular carcinoma invasion ; 
 Histological   confirmation of  capsular  invasion and /or vascular invasion  
is necessary  for the diagnosis of  Follicular Thyroid Carcinoma.  
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Capsular invasion  
 Capsular  invasion  remains a controversial issue  in  diagnosis of follicular 
carcinoma of thyroid  .  Complete transgression of the fibrous capsule (the tumor 
has to penetrate the entire thickness of the capsule) should  be considered as  an 
unequivocal evidence of capsular invasion. (71,72)  
 Lang  et al and Franssila et al (45,68)noticed  that ,  nest of tumor cells found   
in the capsule could  be due to  fibrosis  rather  than  invasion.  According to 
Iida’s opinion(73), tumor cells  invading  the  capsule  focally  or   finding  a few 
follicles in the capsule without  an  evidence of   reactive  fibrosis  is insufficient 
to diagnose follicular carcinoma of thyroid .So deeper sectioning of these foci  is 
most important in these cases,  it  may show the tumor cells traversing the entire  
capsular  thickness .But the invading  tumor  nests should show a connection with 
the main tumor mass . 
Problematic features relative to diagnostic interpretation include: 
• Irregular contour(s) of the tumor, 
• Tangential sectioning, 
• Free-floating tumor nests in the capsule may indicate entrapment due to 
preoperative Fine Needle Aspiration  or tumor degeneration. 
• Tumor cells seen  outside the capsule without any connection to the main  
tumor should not be considered as the foci of invasion . 
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• Minimally Invasive  Follicular Carcinoma  exhibited only focal invasion 
either to the capsule or a vessel, whereas widely invasive follicular thyroid 
carcinomas showed widespread infiltration  into adjacent  thyroid tissue  or 
into the vessels . 
 
Figure –5; Adapted from Christopher D M Fletcher, diagnostic 
histopathology of tumors ;Elsilver volume 2 page 1203 
-Section  shows  the tumor bud has actively penetrated   and reaching beyond the 
external  contour of the capsule  like a mushroom fashion. 
 
Vascular invasion 
 Vascular invasion is defined as the presence of an endothelialised  tumor  
cell nests (located within or beyond the fibrous capsule) in the capsular vessels  
adherent to the vessel wall . 
            The histological criteria for diagnosis of vascular invasion are defined as 
follows:(30) 
1. The invasive tumor should form a plug  in  sub endothelial location; 
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2. The tumor thrombus should be  lined by endothelial cells. 
3. The endothelialised tumor embolus  should  be   attached  to the vessel wall. 
4. Tumor cell nests seen freely in a vessel lumen without endothelial covering 
may  indicate  artefacts. 
 
Figure -6;Adapted from ; Baloch ZW, LiVolsi VA. Our approach to 
follicular‐patterned lesions of the thyroid. J Clin Pathol. 2007 
Mar;60(3):244–50. 
-   Section shows  vascular invasion in follicular thyroid carcinoma  showing 
tumour cells invading a capsular vessel; the invading tumour nest is lined by 
endothelial cells (inset). 
    
 Vascular invasion  is the more consistent  feature of malignancy than 
capsular invasion. Mete and Asa recently redefined vascular invasion as “tumor 
cells invading into a vessel wall which is covered  by endothelium, and associated 
with main tumor  adherent to intravascular  tumor thrombus .(74) such criteria are 
too strict for use in diagnosis of follicular carcinoma.Deeper sections and/or 
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elastic stains or trichrome may demonstrate the presence of endothelial lining or 
elastic membranes. because a continuous smooth muscle layer may not be present;  
so these stains usually are of only limited help. Stains for endothelial markers  
such as CD31 ,CD34 Factor VIII related antigen and Ulex Europaeus agglutinin I, 
are of limited  use.(36).                                  
Follicular Carcinoma Categorization(75) 
 According to the extent of the invasive component, two types of follicular  
thyroid carcinoma are recognized which differs  in their biologic behavior and in 
their treatment: 
 1. Minimally invasive (low-grade) follicular carcinoma, 
 which in turn can be Subdivided into: - 
• Have only  capsular invasion, without  angioinvasion   
• With angioinvasion(76) – 
       limited  angioinvasion, including less than 4 vascular spaces 
       Extensive  angioinvasion,- including 4 or  more than 4 vascular spaces.  
2. Widely invasive follicular carcinoma 
o shows widespread  infiltration of the tumor into  the thyroid  
parenchyma  and into  the blood vessels  
o often lack complete encapsulation  
o Penetration of  entire thickness of the  capsule  by the tumor  with or 
without  vascular permeation. 
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 Follicular Carcinoma, Minimally Invasive ;Treatment and prognosis; 
 Baloch  and  LiVolsi  reported that  encapsulated  follicular tumors  
showing only capsular invasion as minimally invasive follicular carcinoma and 
these tumors were believed  to have a low risk of  recurrence  or  metastases.(30) 
 Treatment options  of minimally invasive follicular carcinoma include 
conservative treatment versus more  radical approaches(77) 
 Conservative therapy includes limited resection (lobectomy or subtotal 
thyroidectomy) without radioactive iodine. 
 Radical therapeutic intervention  includes total  thyroidectomy followed by 
administration of radioactive iodine. 
 Conservative modalities are utilised only for the tumors with  limited 
invasion and the absence of metastases. In the evidence of any metastasis, the 
patients should  be treated with  radioactive iodine.  D’Avanzo(55)  reported that 
10-year survival  of patients with minimally invasive follicular carcinoma  of 
thyroid is  98%.But  the prognosis  mainly depends on extent of capsular and 
vascular permeation. The long term prognosis for  the tumors  with only capsular  
permeation   is excellent and the risk of metastasis is very  low  approximately 
0.1%(55).Prognosis is also considered good for the tumors with  limited  
angioinvasion. But the prognosis for  tumors with extensive angioinvasion is 
guarded. 
Follicular Carcinoma, Widely Invasive Treatment and Prognosis ; 
 For Widely  Invasive    Follicular thyroid  Carcinoma -  more  aggressive 
treatment is required which  includes total thyroidectomy  and radioactive iodine 
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therapy . Prognosis   is generally  poor, but  it is  variable. These  tumors  shows  
hematogenous  spread with  metastasis to bone, lungs , brain and skin. Metastatic 
disease may be identified  at an  early stage  of the disease  and radioactive iodine 
should be given at this stage  . The metastatic foci appears  histologically similar 
to the primary tumor. A  10 year survival  of patients with angioinvasive follicular 
carcinoma  with or without capsular invasion is 80% and 38% with extensive 
capsular  invasion of the tumor and the adjacent  thyroid parenchyma (55). The 
cause of death is due to distant metastases .(78) 
Adverse prognostic factors of  follicular thyroid  carcinoma include(79): 
- presence of extraglandular spread into adjacent soft tissues; 
- presence of distant metastasis; 
- older age of the patient (over 40 years); 
- male gender may be associated with a worse prognosis; 
- extensive intrathyroidal invasion; 
- presence of intravascular invasion; 
- tumor size: tumors size more than  4  cm have a worse prognosis; 
- Histologic type- solid/trabecular pattern-worse prognosis 
 
 
f) Follicular Carcinoma is further classified based on the tissue pattern as 
follows; 
   Oncocytic (Hürthle) cell variant 
   Signet ring cell variant 
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   Clear cell variant 
   Mucinous variant 
  Hyalinising trabecular carcinoma. 
 
3.8.2) Follicular carcinoma oncocytic type (Hurthle cell variant) 
 
                     HURTHLE CELL CARCINOMA- ANGIOINVASIVE 
 
Figure – 7;Adapted from Rosai J, Carangui ML, DeLellis RA (1992) Atlas of 
tumor pathology: tumors of the thyroid gland. Armed Forces Institute of 
Pathology, Washington, DC 
-Section shows endothelialized tumor embolus in the vascular                 
space,tumor proper on the right (H&E 10x) 
o Frequency of malignancy is higher  in older age group (35%)(80)   
o higher prevalence of aggressive behavior 
o larger size (≥4cm strongly correlated to malignancy) 
o higher frequency of extrathyroidal extension, 
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o greater inclination to regional node and distant metastases 
o lower survival rate 
3.9)  Role  of immunohistochemistry in follicular neoplasm of thyroid 
 The histopathological diagnosis of follicular neoplasm of thyroid remains 
the cornerstone in the classification of follicular thyroid lesions. Recent studies 
have concentrated on identifying immunohistochemical markers  which are used 
to distinguish  benign  from malignant  follicular thyroid tumors, (follicular 
adenoma and follicular  carcinoma and  to differentiate follicular variant of 
papillary thyroid  carcinoma from  follicular carcinoma and  adenoma of thyroid) . 
In this view number of  growing  immunomarkers have been tested, and some  of  
them are found to be promising  like CD56, Hector Battifora Mesothelial 1 
(HBME-1), Galectin  - 3 and  Cytokeratin -19 (81,82).                      
 Nevertheless,   there is no  single  immunomarker  sensitive enough to 
provide a definitive malignant diagnosis. As proposed by many investigators a  
panel of  immunohistochemical markers are  recommended in folliculartumors  to 
improve  diagnostic accuracy. Galectin 3 and  CD56  made   significant difference 
between follicular adenoma and follicular carcinoma of thyroid. Galectin 3  was 
the only marker which made  statistically significant difference between adenoma 
and carcinoma of Hurthle cells. Galectin- 3 is a sensitive marker for malignancy, 
while  the negative expression of CD56 is very specific for malignancy. But CD56  
and  Galectin-3 could not be able to differentiate between follicular variant of 
papillary carcinoma and follicular carcinoma of thyroid . The combination  panel 
of  2 or  3 markers   also given  promising results. 
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 -Various other antibodies have also been studied for their potential value in 
the distinction between follicular carcinoma and adenoma of thyroid, but none so 
far has been shown to be foolproof. 
 Immune staining  for endothelial markers has not been very successful for 
detecting vascular invasion, because the staining may be erratic.(83) 
  Although some antibodies such as tissue polypeptide antigen, dipeptidyl 
amino peptidase IV, Leu-7, thyroperoxidase (MoAb47), matrix 
metalloproteinase-2, matrixmetalloproteinase-7, and cyclooxygenase-2 are 
reported to show differential staining of follicular adenomas and follicular 
carcinomas(15,84,85) 
3.10) Immunohistochemical markers 
3.10.1   GALECTIN  3 
 GALECTIN- 3 (31 kD) is a  beta-galactosidase binding  lectin. It belongs 
to  the agglutinin family. It is  a kind of multipeptide consisting of a short amino-
terminal sequence, which is a repetitive collagen-like sequence that is rich in 
proline, glycine, and tyrosine and a Carboxy terminal.(86) Galectins are localized 
on the cell surface, within the extracellular matrix, as well as in the cytoplasm and 
the nucleus of the  cells. It  may serve as  the  receptors for  extracellular matrix 
proteins, such as laminin and fibronectin (87). Galectin-3 is able to make cross 
links with cell membrane glycoproteins, thus forming new network involved in 
cellular signaling of   receptors. Galectins are expressed in  thyroid , breast, colon 
and as well as in macrophages and activated endothelial cells, and they  play a 
vital role in  number of biological processes such as  cell growth, differentiation, 
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apoptosis, inflammation, and angiogenesis, tumor progression.(88) Galectin-3 is 
known to mediate and inhibit cell adhesion and  participate in neutrophil and 
macrophage activation. Galectin-3 works as redundant pre-mRNA splicing factor, 
regulates the cell cycle and apoptosis, being either anti-apoptotic or proapoptotic. 
According to a recent study (88) serum gal3 increased significantly in patients with 
breast, gastrointestinal, lung and ovarian cancer, as well as in patients with 
melanoma and non-Hodgkin’s lymphoma. These authors also reported that the 
level of serum gal3 of patients with metastatic disease was higher than in patients 
with a localized tumor. This proves that circulating gal3 may have arole in tumor 
progression and, based on this, assay of gal3 carried out in an early stage could 
predict the metastatic potential of the tumor. 
 Several studies have analyzed galectin-1 and galectin-3 expression in 
benign and malignant thyroid tissue. Several studies have recently challenged  
galectin-3 as a tumour marker for follicular carcinoma  of thyroid . Galectin-3 is 
also a fairly reliable marker in distinguishing follicular adenomas and carcinomas; 
however, it should be combined with other markers to increase its accuracy. . 
Galectin 3 is a marker of early malignant transformation and minimally invasive 
carcinoma.(89) .Several authors emphasize that the galectin-3positive and 
morphologically suspect follicular adenomas (with cellular atypia) can be 
considered potentially as early carcinomas, in which capsular and vascular 
invasion cannot be observed  yet, but transformation at the molecular level  may 
have   been  already occurred ,(90) 
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 Recent studies, found difference in expression of Galectin 3 between follicular 
thyroid  carcinoma and follicular adenoma . Galectin 3 was the only marker able 
to make a difference between Hurthle cell carcinoma and adenoma, which is also 
confirmed by the study .(91) 
STANINIG PATTERN OF GALECTIN 3; 
 With reference  to the study (92)  if   more than 5% of the tumour cells shows 
cytoplasmic staining for Galectin-3, then they were scored as positive regardless 
of  their intensity.  Distribution and intensity of Galectin -3 interpretation was 
based on the study followed by Weber KB et al. and Hermann ME et al., (92,93)The 
staining intensity was graded on a scale of 0 to 3 where 0, 1+, 2+, and 3+ denote 
no staining, weak/ slight staining, moderate staining and intense staining 
respectively, and the proportion of stained cells were interpreted as 1+ (less than 
5% of cells), 2+ (5% to 50% of cells) and 3+ (more than 50% of cells) (93) 
Intensity of staining of cells; 
1 = weak 
 2 =moderate 
 3 = strong   
 
Proportion   of  cells  showing positive expression for  Galectin - 3; 
     1+  (less than 5% of cells) 
     2+  (5% to 50% of cells)  
     3+  (more than50% of cells)    
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Cytoplasmic galectin-3 expression was found only in carcinomas, and therefore it 
may be considered an evidence of malignancy. Cytoplasmic predominance  of 
galectin-3expression  has been related to  the progression of normal tissue to 
adenoma and carcinoma.It was studied  in the colon carcinoma model .Galectin-3 
may play an important role in malignant transformation, especially in cell 
adherence and metastasis.  (94) 
3.10.2)  CD56 
 CD56 (NCAM)- Neural cell adhesion molecule, Leu19) is a homophilic 
binding membrane glycoprotein  of Ig-superfamily that has an important role in 
cell-to-cell adhesion.It is expressed normally in Natural Killer cells (NK cells), 
activated T cells, large granular lymphocytes, brain tissue and specific 
endocrines(95) thyroid follicular cells  Previous studies have demonstrated that 
CD56 is present in the normal follicular cells of the thyroid  also in benign thyroid 
lesions (thyroid follicular adenomas, chronic autoimmune thyroiditis, nodular 
goiter or Basedow disease), but its expression is low or absent when malignant 
transformation occurs.(96) 
 Reduced expression of CD56 has been implicated with tumor progression 
of the patient with cancer. Loss of CD56 expression was associated with 
metastatic potential and a poor prognosis in some malignant tumors. A study by 
Artuset al showed increased expression of CD56 in follicular adenomas than the 
surrounding thyroid tissue and decreased CD56 expression in follicular thyroid 
carcinoma than the benign thyroid tissue(82). Its expression is reduced, or totally 
lost, in cases of papillary carcinoma, follicular carcinoma and anaplastic 
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carcinoma The most specific combination of markers CD56andGAL 3 reduces 
sensitivity and increases specificity for malignancy. Cases were considered CD56 
positive if they showed cytoplasmic ± membranous staining in ≥10% of the cells 
.(97) 
The immunostained slides were evaluated for the 
 Extent(percentage) of positive cells ; 
 0: <10% (For CD56, focal cytoplasmic and membranous reactivity of up to 10% 
was considered negative). 
 1+: 10-25% 
 2+: >25-50%, 
 3+: >50 % 
Intensity of staining reaction; 
 1 = weak 
 2 =moderate 
 3 = strong   
 A total score was calculated by summation of the  forementioned  extent and 
intensity scores. 
 
3.10.3) HBME-1 
 HBME1 (Hector Battifora Mesothelial 1), is  a monoclonal antibody which 
reacts with  uncharacterized  antibody in microvilli of mesothelial cells, tracheal 
epithelium, and adenocarcinomas of  the pancreas, lung, and breast (98).Hector 
Battifora mesothelial-1 (HBME-1)has been noticed as an  important  thyroid 
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marker of follicular origin, with greater affinity to malignant tumors when 
compared to benign lesions. 
              HBME-1 has been studied  in  many thyroid tumors  with the aim to 
differentiate  benign from malignant lesions. Follicular variant of papillary 
carcinoma has significantly higher expression of this marker  than follicular 
adenoma or follicular carcinoma..The results of a few other studies were  also 
showing higher expression of HBME-1 in follicular carcinoma than in follicular 
adenoma. The staining pattern is membranous ± cytoplasmatic immunoreactivity 
for HBME- 1. (99) 
3.10.4) CK 19 
 Cytokeratin 19 belongs to  intermediate filaments of cytokeratins family. 
Normally  it is expressed in simple and  glandular epithelium, basal layer of 
stratified epithelium, and in hair follicles . Normal thyroid follicular cells do not 
produce this protein, so upregulation of CK19 is connected with neoplastic 
transformation. Strong and diffuse membranous ± cytoplasmatic 
immunoreactivity  of CK19 is most often related to papillary thyroid carcinoma 
.(100) Cytokeratin-19 (CK-19) expression in thyroid nodules is   intense and diffuse 
in papillary carcinoma and variable  expression in  follicular thyroid carcinoma 
and in follicular adenoma, with nil or low expression in other benign lesions. Due 
to its low specificity, CK19 is not suitable for use in the differential diagnosis of 
suspected follicular-patterned lesions. 
3.10.5)  p27 
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 The  CDK inhibitor p27( p27/KIP 1) which is  located on 
chromosome12p13 and encoded by CDKN1B gene, regulates cell proliferation, 
cell motility, and apoptosis. Phosphorylation regulates  p27 inhibition of cyclin-
CDK complexes, its localization, and its ubiquitin-mediated proteolysis during G0 
and early G1 phases of the cell cycle.Thus preventing entry to S phase through 
activation of retinoblastoma protein. Normal epithelia of breast, prostate, ovary, 
lung, and other sites express high levels of nuclear p27(42). 
 Normal thyroid follicular epithelium shows strong nuclear immune 
reactivity for p27. The  significant difference of p27 expression  is found between 
follicular thyroid  adenoma and follicular-derived  thyroid carcinoma. Loss of p27 
is an early event in follicular tumor genesis, which starts at minimally invasive 
carcinomas .Some investigators have  reported a higher immune reactivity for p27 
in the follicular variant of papillary thyroid carcinoma, in comparison with 
classical Papillary Thyroid Carcinoma (PTC). A variable loss of p27 protein has 
been shown in many human tumors. p27 is reduced in premalignant and 
noninvasive cancerous lesions, including ductal carcinoma in situ of the breast, 
aggressive ovarian cancers and  oral dysplasia .It is  the prognostic for subsequent 
development of oral squamous carcinoma.  
 Reduced p27 expression  was also found in normal oral mucosa adjacent to 
tumor tissue ,benign prostatic hypertrophy, a hyperplastic premalignant prostatic 
neoplasm, and in ovarian tumors of low malignant potential . 
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3.10.6) CD44v6 
 CD44, also known as extracellular matrix receptor III, hyaluronate 
receptor, and heparan sulfate proteoglycan, belongs to a family of 
immunologically related integral membrane glycoproteins that bind  hyaluronic  
acid. CD44  has affinity for hyaluronic acid and the  ligands, such as osteopontin, 
collagens, and matrix metalloproteinases  and mediates cell-cell and cell-matrix 
interactions. Adhesion with hyaluronic acid plays.an vital role in cell migration, 
tumor growth, and progression. The CD44 gene, located on chromosome 11, 
consists of at least 19 exons (101).Isoforms sharing CD44 variant exon 6 are known 
to cause tumor invasiveness and metastatic potential in malignant rat cell line. 
CD44v6 has been analysed on thyroid lesions by immunohistochemistry in 
surgical specimens and fine-needle aspirates. Intense membrane staining has been  
demonstrated in well-differentiated papillary and follicular carcinomas show the 
highest immunoreactivity for CD44v6(75%–90% and 90%–100%, 
respectively).(102) Its  expression also been detected in poorly differentiated and 
anaplastic carcinomas, medullary carcinomas ,oncocytic variant follicular and 
papillary carcinomas of thyroid  and also  in benign lesions including  
hyperplastic nodules (40%) and follicular adenomas (30%–43%).(103).  From these 
findings it was  suggested  that CD44v6 may be correlated with deregulation of  
follicular proliferation, rather than malignant transformation, so  it should not be 
used as a single marker to discriminate benign from malignant thyroid lesions. 
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3.10.7) Thyroid  Transcription Factor 1 (TTF-1) 
 Thyroid Transcription Factor-1(TTF-1) is a nuclear tissue-specific protein 
which interacts with  Thyroglobulin(TG)  gene.TTF-1 controls the gene 
expression in thyroid, lungs, and diencephalon during embryogenesis. TTF-1 in 
association  with PAX8 regulates  the expression of Thyroglobulin(TG)  gene , 
ThyroPeroxidase (TPO), thyrotrophic receptor in the thyroid. In the lung, TTF-1 
regulates the expression of surfactant proteins(18). Since  TTF-1 expression is 
highly specific for thyroid and lung tumors, it has been widely used to detect  the 
primary site of tumor origin in patients with metastatic disease of unknown origin. 
TTF-1 immunoreactivity is identified  in pulmonary tumors, including 
neuroendocrine tumors, and rarely in small cell carcinomas from other sites.(104) In 
the thyroid, nuclear reactivity for TTF-1 is present in  benign and malignant 
follicular  lesions  and medullary  thyroid carcinomas. Poorly differentiated 
carcinomas  usually  show weak  and focal staining for TTF-1.Most anaplastic 
carcinomas lack TTF-1 reactivity.(105) When used in combination with 
thyroglobulin, TTF-1 is an effective marker for thyroid origin. Lack of TTF-1  
immunoreactivity  in a thyroid tumor should warrant the investigation for  other 
differential diagnoses, such as parathyroid tumors, paragangliomas, and metastatic 
tumors. 
3.10.8) Thyroperoxidase(TPO) 
 Thyroperoxidase is a thyroid-specific enzyme (monoclonal antibody 47) 
reflecting normal thyroid function. Thyroperoxidase expression is demonstrated in 
normal thyroid follicular epithelial cells, usually in diffuse fashion(106). During 
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thyroid cell dedifferentiation, the expression of TPO is lost. Therefore, lack of 
TPO expression is regarded as a marker of malignancy. Several studies (107) 
investigated the diagnostic utility of Thyroperoxidase(TPO) in thyroid lesions, 
yielding a sensitivity of 90% for Papillary Thyroid Carcinoma( PTC )and 76% for 
Follicular Thyroid Carcinoma( FTC) and a specificity of 88%.. The earlier studies 
produced more promising results than recent ones. Thyroperoxidase appears  to be 
highly sensitive for Papillary Thyroid Carcinoma but borderline to poorly 
sensitive for Follicular Thyroid Carcinoma. The staining patterns of (TPO) 
follicular  thyroid  carcinoma and follicular adenoma  showed a certain degree of 
overlapping without meaningful discriminatory value. A couple of recent 
studies(108) used a combination of TPO and GALECTIN -3 to improve diagnostic 
accuracy  
3.10.9)  CYCLIN D1 
 Cell cycle related genes include promoters and inhibitors.  Promoters are 
are Cyclin D and E and inhibitors are p27, p53 and retinoblastoma (RB) protein. 
The promoters are considered oncogenes and the inhibitors are  tumor suppressor 
genes. The most studied promoter of the cell cycle is Cyclin D.It  is  a member of 
the family of cyclins, is a 36-kD nuclear protein that functions as the regulatory 
subunit of cyclin-dependent kinases (CDK4 and CDK6). It is a key regulator of 
the G1/S transition through the cell cycle by inactivating RB protein. (109) Cyclin 
D1, encoded by human CCND1 gene, which is one of the most frequently 
amplified genes in human cancers. Deregulation of cyclin D expression results in 
the loss of control of normal cell growth and oncogenesis. Overexpression of 
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cyclin D1 has been demonstrated in various human cancers, including thyroid 
carcinomas.(110)  Normal thyrocytes are immunohistochemically negative for 
cyclin D1. Wang  et al (111) investigated cyclin D1 expression in 34 conventional 
papillary thyroid carcinomas, 10 minimally invasive follicular thyroid carcinomas, 
and 32  aggressive thyroid carcinomas. Their study demonstrated overexpression 
of cyclin D1 is found  in most  of the aggressive thyroid carcinomas  
3.10.10)  E-cadherin 
 E-cadherin is  a calcium-dependent transmembrane cell adhesion molecule, 
is required for normal epithelial function. Down-regulation of E-cadherin 
expression has been observed in various carcinomas and it  is usually associated 
with an advanced stage of tumour  and  tumour progression.(112) In normal and 
benign thyroid lesions, high expression of Ecadherin was demonstrated .In thyroid 
carcinomas, E-cadherin expression was reduced in poorly differentiated 
carcinomas, lost in undifferentiated carcinomas, and preserved in most minimally 
invasive carcinomas of thyroid. The studies suggest that loss of E-cadherin 
expression is the crucial event in dedifferentiation, progression, and metastatic 
spread of thyroid carcinomas.(113) 
3.10.11) Fibronectins (FNs) 
 Fibronectins  are    extracellular  matrix proteins produced by fibroblasts, 
are involved in cell adhesion, migration, and tumor progression. Oncofetal FNs, 
isoforms of fibronectin , are highly expressed in fetal and neoplastic tissues, 
especially  in papillary thyroid carcinomas. Fibronectin-1 (FN-1) is upregulated in 
thyroid carcinomas as compared with normal thyroid tissue(114). In the study of 
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Prasad and colleagues,137  fibronectin was present in 91% of papillary carcinomas, 
50% of follicular carcinomas,100% of anaplastic carcinomas, 75% hurthle cell 
carcinomas, 5% of follicular adenomas, and 7% of nodular goiters.(115) 
 3.10.12)  Beta-catenin, 
 Beta-catenin is a 92-kD multifunctional protein, plays an important role in 
cell adhesion and signal transduction and serves as a downstream effector in the 
Wnt signaling pathway. The CTNNB1 gene encodes β-catenin. In normal resting 
cells, beta-catenin forms cytoplasmic/membranous-bound complexes with E-
cadherin. Upon activation, beta-catenin translocates to the nucleus, promoting 
tumor growth through activation of the Wnt signaling pathway. Normal thyroid 
follicular cells display a strong membranous  immunoreactivity for beta catenin. 
Along with E-cadherin, loss of membranous  beta -catenin immunostaining is an 
indicator for loss of differentiation and adverse prognosis(116).The association of 
aberrant nuclear beta-catenin expression and poor prognosis was observed by 
some investigators. (117). Point mutations of CTNNB1 occur in 25% and 66% of 
poorly differentiated and undifferentiated thyroid carcinomas, respectively.(118)   
The membrane expression of  β-catenin is reduced in follicular cell adenomas and 
carcinomas. 
3.10.13)  p53 
 p53  is a tumor suppressor  gene that plays an important  role in normal  
cell growth. Mutations of the P53 gene lead to accumulation of p53, which can be 
detected by immunohistochemistry. p53 is one of the highest  associative   genes 
found in  human cancers  so far. In the process of gene mutation, function of p53 
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is also changed, losing the function of inhibiting tumor genesis. Recently, it has 
been discovered that p53 mutation is related  to different types of thyroid 
carcinoma. In the series reported by Soares and coworkers, p53 was absent from 
14 cases of goiter and adenoma and from 12 cases of papillary thyroid  carcinoma. 
(119)p53 was present in 20% of follicular carcinomas (predominantly of the widely 
invasive type), 16% of poorly differentiated carcinomas, and 67% of 
undifferentiated carcinomas. In the series reported by Holm and Nesland, 6 of 32 
(19%) papillary carcinomas, 5 of 29 (17%) follicular carcinomas, and 18 of 24 
(75%) undifferentiated carcinomas were positive for  p53(120). The p53 mutation 
has an effect on infiltration, lymphatic metastasis and prognosis of thyroid 
carcinoma. Mutations and over expression of the p53 gene are common in head 
and neck squamous cell carcinoma,  bladder carcinomas, anaplastic ependymomas 
and pancreatic intraepithelial neoplasia -3(PIN-3). 
 3.10.14)  Telomerase  
 Telomerase is a kind of reverse transcriptase, that  can replicate on the 
template of its own RNA. It can sustain the length of telomere  , in order to escape 
apolexis, death and obtain cell  immortalization. Therefore telomerase aberrant 
activation leads to the infinite multiplication of tumor cells. Umbricht(121) reported 
that telomerase is helpful in  discriminating  follicular thyroid adenoma from 
follicular thyroid carcinoma. In follicular thyroid carcinoma, telomerase  
expression  is 100% whereas it is only 19% in  the case of follicular  thyroid 
adenoma. Saji(122) reported   hTERT expression in the  samples of thyroid nodule 
and  in normal thyroid tissues. And  it was observed that, hTERT expression in  
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follicular carcinoma of  thyroid is  higher (100%), 69.2% in Papillary Thyroid 
Carcinoma, 28% in  the benign thyroid nodules, and  normal tissues showed  no 
expression. Therefore, telomerase- reverse transcriptase  expression is  significant 
in understanding thyroid carcinoma pathogenesis, diagnosis, therapy and 
prognosis. 
3.10.15)  Matrix Metallo Proteinase  (MMP) -1, 9 
 Matrix Metallo Proteinase  is a group of zinc ions dependent proteinase 
family, that  can cause degradation of  the matrix membrane skeleton  . It has been 
known that invasion of  blood vessel  by the tumor is necessary to distinguish 
thyroid follicular cancer from thyroid adenoma. This  infiltration is achieved   by 
degrading collagen in the basement  membrane located under blood vessel 
endothelium, which forms the mechanism of follicular cancer haematogenous 
metastasis. MMP-1 is one of MMP family members,  it is a interstitial  
collagenase and may degrade type I, II, III collagen. MMP-9 (gelatinase B) is the 
other member of MMP family, and it mainly acts to gelatin and IV/V type 
collagen. The MMP-9  expression was  more  in  follicular  thyroid cancer, than 
the follicular adenoma.(123)  
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Given below is a table of common IHC markers used in tumors of thyroid 
gland 
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4. MATERIALS AND METHODS 
 
           This retrospective study material include the cases of  benign and 
malignant follicular tumors of thyroid  that were diagnosed using Hematoxylin 
and Eosin stain  in the Department of Pathology, Tirunelveli Medical College and 
from the Department of Pathology, Thoothukudi Medical College during a period 
of June 2014 to June 2017  
4.1) Study design 
 Retrospective study 
4.2) Inclusion criteria 
 All the cases  that were reported as follicular adenoma and its variants, 
follicular carcinoma of thyroid and its variants  using Hematoxylin and Eosin 
stain (H &E) are included. 
 The  blocks and slides of the respective cases are collected. 
4.3) Exclusion criteria 
 a)   The thyroid tumors other than follicular tumors of thyroid  
    b)    Autolysed specimens     
c)   Poorly processed material  
         d)  Cases with dense tissue necrosis 
4.4 ) Sample size 
           A total number of 45 cases of  surgically resected follicular thyroid tumors 
that include both benign and malignant follicular thyroid tumors were collected. 
Out of 45 cases 33 cases were benign  follicular tumors that includes (n= 32) 
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Follicular adenoma  and (n=1) Hyalinising Trabecular Adenoma and12 cases were  
malignant follicular tumors of thyroid that includes (Widely invasive Follicular 
Carcinoma (n=4), Minimally Invasive Follicular Carcinoma (n=7), Hurthle Cell 
Carcinoma( n=1) were collected. 
4.5 ) Materials required 
(1) Donor blocks which contains formalin fixed paraffin embedded tissue 
obtained from all the cases of follicular tumors of thyroid. 
(2)  Hematoxylin and eosin stained tissue sections made from the donor 
blocks. 
(3) Postively charged slides for holding tissue sections for IHC 
(4) Chemicals for preparing antigen retrieval solutions and for wash buffers 
(5) Pressure cooker  for antigen retrieval. 
(6) Kits for performing immunohistochemistry which includes primary 
antibodies (CD56 and GALECTIN 3) and universal kit. 
(7) Microscope used for grading of IHC slides  
4.6 Methodology  
COLLECTION OF DONOR BLOCKS AND SLIDES 
 The details  of the patient  such as  age, gender, thyroid status, 
ultrasonogram findings, previous  thyroid surgeries, FNAC report were collected 
from the clinical case sheets and from the Medical Records Department of 
Tirunelveli Medical College Hospital and  Thoothukudi Medical College 
Hospital. Gross findings regarding size of the lesion, capsular (thick or thin) 
details, histopathological diagnosis  were collected from the general surgical 
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report register, who were operated between   the period of June 2014 to June 
2017. 
The following cases were selected in histological sections – 
         a) the diagnosis of follicular adenoma was made based on the presence of 
encapsulated mass with homogenous follicular proliferation ,lack of papillary 
thyroid carcinomas  features and absence of vascular and /or capsular invasion. 
                 b) Follicular carcinoma of thyroid  was diagnosed based on tumor with   
thick capsule , full capsular and/or vascular invasion  by the tumor cells , and  
atypical  hyperchromatic  nuclei that lacked features of Papillary Thyroid 
Carcinoma . 
 Either an endothelium-surrounded tumor cells as a thrombus or a 
penetrating mass into a vessel indicate a vascular invasion. Capsular invasion was 
comprehended as the penetration of the tumor tissue through the capsule.. 
Minimally invasive follicular thyroid carcinoma exhibited only focal invasion 
either to the capsule into a vessel, whereas widely invasive follicular thyroid 
carcinoma   showed widespread infiltration into adjacent thyroid tissue or into  the 
vessels. 
COLLECTION OF CONTROL BLOCKS 
 Control tissues included in this study  were , mucosa of appendix (crypts 
positive to  Gal-3), muscular layer of appendix (nerve fibers and ganglion cells 
positive for CD56). 
 
 
 
 
49 
 
PREPARATION OF HAEMATOXYLIN AND EOSIN SLIDES  
 The sections which were prepared from 10% formalin fixed paraffin 
embedded blocks of all cases of  both benign and malignant follicular thyroid 
tumors were collected. A  section of  4 microns thickness were made. Slides were 
stained with routine H&E stains. The archival tumors were initially fixed into 
formalin in order to preserve the structure of the tissue and stop metabolism of the 
cells. Paraffn embedding was performed, by washing and dehydration with 
ascending series of alcohol solutions and diluting in an organic solvent, in order to 
harden the tissue to be cut into thin slides with a microtome.Archived paraffin 
blocks were cut with a microtome and paraffn was dissolved with a solvent and 
rehydrated with descending alcohol series.  
 Haematoxylin stain was performed in water and counterstained with eosin 
in alcohol after dehydration. Finally, the stained slides were mounted with a non-
aqueous medium and a coverslip. Haematoxylin stains the cytoplasm of the cell 
into pinkish colour whereas eosin stains the nuclei as blue (HE stain) . 
SLIDE PREPARATION FOR IHC 
Section cutting; 
                Sections were taken at 5microns thickness  on the surface of the APES 
(3-aminopropyltriethoxysilane) coated slides. This was followed by incubation of 
slides at 60-70C for 1 hour . 
Antigen retrieval solution; 
 We used  antigen retrieval solution and a wash buffer as prescribed by the 
manufacturer (PATH INSITU). 
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 1. Tris EDTA buffer at a PH of 9 . 
 2. Tris wash buffer at PH  of  7.6. 
 
BUFFER PREPARATION 
TRIS  EDTA BUFFER 
 Tris –6.05gm 
 EDTA--O.744gm 
 1 N HCL—4ml 
 Distilled water—1litre 
TRIS WASH BUFFER 
 Tris -6.05gm 
 Sodium chloride -8gm 
 1N HCL-4ml 
 Distilled water-1 litre 
PRECAUTIONS 
a)  The glassware of  immunohistochemistry must be  clean and dry 
b)  The buffer used should be prepared fresh and adequate  pH must be achieved 
by adjusting  accordingly.  
c)  During  the process of immunohistochemistry , the slide should never be 
allowed to dry, and so a humidity chamber is used during staining and 
incubation. 
d) DAB chromogen  should be handled carefully as it is potentially 
carcinogenic. 
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e)  All reagents –primary  antibody ,DAB chromogen, Peroxidase block should 
be stored at ideal 4- 6 degree celcius 
f)  Every batch of slide should accompanied by positive and negative controls 
which ensures quality of the procedure. 
PROCEDURE 
Antigen retrieval; 
 Many methods have been used for antigen retrieval which includes 
Microwave method, and water bath, autoclave, proteolytic enzyme and pressure 
cooker method. In our institution we followed antigen retrieval by using pressure 
cooker method ,as it produces even heating with lesser disadvantages as compared 
to other methods.  
Procedure for immunohistochemistry as given by manufacturer; 
1.  Section cutting and incubation is followed by Xylene wash (3 changes) for 
15minutes each. 
2.  Rehydrated in graded alchohol containing 100%, 80%, 70% for five minutes 
each. 
3.  Rinsed in distilled water for 2minutes each. 
4.  Antigen retrieval for 15-20 minutes in Tris-EDTA buffer and ph of the 
retrievl buffer adjusted to 9. 
5. washed in distilled water, two changes, 2 minutes each. 
6.  Washed in TRIS wash buffer- 3changes 5minutes each. 
7.  Do endogeneous peroxidase  blocking by adding H2O2 on the section, for 7-
10minutes. 
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8.  Washed in TRIS wash buffer- 3changes 10minutes each. 
9.  Application of primary antibody (CD 56 and GALECTIN 3) – 30 mins in 
moist chamber. 
10. Washed in TRIS wash buffer- 3changes 10minutes each. 
11.  Add  polyexcel Target binder for 15 mins 
12.  Washed in TRIS wash buffer- 3changes 10minutes each 
13.  Application of HRP POLYMERASE for 15 mins. 
14.  Washed in TBS wash buffer- 3changes 10minutes each. 
15.  Application of  Diamino-benzidine tetrachloride(DAB) chromogen (1 
 drop) and DAB buffer (1ml) for 5 mins. 
16.  Washed in distilled water – 2 changes. 
17.  Counterstaining with Harris Hematoxylin – 1dip/30seconds to impart 
 background staining. 
18.  Wash in running tap water. 
19.  Dehydrate (70%,80%,100%) 5minutes  
20.   Clear with  xylene – 2 changes 5 minutes each. 
21.  Mount the section with Dextrene Phthalate Xylene 
22.  Observation and grading under light microscope. 
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ANTIBODIES USED 
Antibodies Clone Dilution Manufacturer 
Antigen 
Retrival 
buffer 
TRIS 
Buffer 
pH 
Visualisation 
kit 
manufacturer 
Cd 56 123c3 Prediluted Pathin situ 
Tris 
EDTA 
9 Pathin situ 
Galectin 3 b2c10 Prediluted Pathin situ 
Tris 
EDTA 
9 Pathin situ 
       4.7 GRADING OF IHC STAINIG; 
IHC Grading of GALECTIN 3; 
 Cytoplasmatic ± nuclear immunoreactivity for Gal-3, more than 5 % of 
cells was considered as positive staining without regard to intensity of staining.  
Intensity of staining of cells; 
1 = weak 
 2 =moderate 
 3 = strong   
Propotion of cells stained 
      1+ (< 5% of cells) 
       2+ (5% to 50% of cells)  
       3+ (>50% of cells)    
IHC GRADING OF CD56 
 Strong and complete membranous expression with or without  cytoplasmic  
staining of the cells qualified the case as positive for CD56.  
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 Extent (percentage) of positive cells 
   0  :  <10% 
 1+: 10-25% 
 2+: >25-50%, 
 3+: >50 % 
Intensity of staining reaction; 
 1 = weak 
 2 =moderate 
 3 = strong   
 A total score was calculated by summation of the fore mentioned (Extent + 
intensity) scores. 
 
PROBLEM  TROBULESHOOTING  IN  IHC STAINING  OF CD56 AND 
GALECTIN 3 IN THIS STUDY. 
 Inspite of the strong and diffuse staining of imunohistochemical markers 
CD56 and Galectin 3, in few sections we could not differentiate between 
membranous  and  cytoplasmic  staining  of   the cells. This is  due to  the  intense 
background staining of colloid in immunohistochemistry. 
BLOCKING BACKGROUND STAINIG 
 Background staining  is the unwanted staining of cells in the section. The 
common causes for background staining in immunohistochemistry are either due 
to non specific antibody binding to endogenous Fc receptors or due to 
hydrophobic - ionic interactions and endogenous enzyme activity. Background 
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staining   may be specific or non specific. Specific background staining occurs 
due to  an apparent affinity of certain tissue components to the applied 
antibodies.Non specific background staining  may due to the presence of charged 
sites in the tissue section. 
 Background staining can be minimised by adding a innocuous protein 
solution to the section s before applying the primary antibody. The applied protein 
should saturate and neutralise the charged sites thus enabling the primary antibody 
to bind to the antigenic site only. Blocking of endogenous enzymatic activity  
should be done  before addition of enzyme labelled secondary  reagent to prevent 
the inactivation of enzyme. 
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5. OBSERVATION  AND  RESULTS 
 This  retrospective  study  includes  totally 45 cases  of follicular thyroid  
tumors. Of them, 33 cases  were benign  (n=32,Follicular  adenoma and 
n=1,Hyalinising trabecular adenoma)  constituting  73% and the remaining 12  
cases are malignant (Follicular  thyroid carcinoma) constituting  27%. 
TABLE -1.      DISTRIBUTION OF CASES 
  NO. OF CASES PERCENTAGE 
BENIGN n=33 73% 
MALIGNANT n=12 27% 
 
CHART- 1 
 
TABLE - 2.   DISTRIBUTION OF BENIGN CASES 
              CASES NUMBER 
FOLLICULAR ADENOMA 32 
HYALINISING TRABECULAR ADENOMA 1 
73%
27%
DISTRIBUTION OF CASES
BENIGN
MALIGNANT
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TABLE -3.   DISTRIBUTION OF MALIGNANT CASES 
CASES NUMBER 
WIDELY  INVASIVE FOLLICULAR CARCINOMA (WIFC) 4 
 MINIMALLY INVASIVE     FOLLICULAR CARCINOMA  
(MIFC) 
7 
 HURTHLE  CELL  CARCINOMA (HCC) 1 
 
TABLE -4.   DISTRIBUTION  OF  SAMPLE  BASED  ON  GENDER 
GENDER NO. OF CASES PERCENTAGE 
FEMALES 37 82% 
MALES 8 18% 
 
CHART - 2 .   DISTRIBUTION  OF SAMPLE BASED ON GENDER
 
 
82%
18%
FEMALES
MALES
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     According to the study(2),  females were affected more common than males  
in  follicular  neoplasm of thyroid. In our study also  females (82%) were more 
affected than males(18%)  in both  follicular adenoma and follicular carcinoma of 
thyroid. 
 
TABLE -5. AGE   WISE   DISTRIBUTION OF SAMPLE 
         AGE  BENIGN MALIGNANT 
20 to 40 years 60% 41% 
41 to 60 years 36% 41% 
61 to 80 years 4% 8% 
 
 
 
CHART - 3.   AGEWISE   DISTRIBUTION OF SAMPLE 
 
        In this study, the age group commonly affected by the benign follicular 
tumors (Follicular adenoma) were between 20 to 63 years, median age  37 +9.47 
60%
36%
4%
41% 41%
8%
0%
10%
20%
30%
40%
50%
60%
70%
20 to 40 41 to 60 61 to 80
Benign Malignant
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SD. The age group commonly affected by malignant tumors (Follicular 
carcinoma) were between 30 to 70 years, median age 42 +14.2 SD. These data 
was found to correlate with the study (2), that most of the follicular tumors were 
common during third to sixth decades of life. 
 
TABLE- 6.   DISTRIBUTION OF SAMPLE BASED ON NATURE OF LESIONS 
 NO.OF CASES PERCENTAGE 
NODULAR  LESIONS 42 93% 
DIFFUSE  LESIONS 3 7% 
 
 
CHART- 4.  DISTRIBUTION OF SAMPLE BASED ON NATURE OF LESIONS 
 
 In this study, nodular lesions were found to be 93% (n=42) and  diffuse  
lesions were only7%(n=3).  According to  Christopher most  of the patients with a 
follicular adenoma or a follicular carcinoma usually presents  with a thyroid 
Nodular lesions
Diffuse lesions
0
10
20
30
40
50
n= 42
n=3
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nodule that is palpable on physical examination or identified on an imaging study. 
Palpable thyroid nodules occur in 4%–7% of the population and up to 60%–70% 
will have a nonpalpable nodule that can be identified by imaging the thyroid gland 
with ultrasound(124) 
TABLE -7.    SAMPLES  BASED ON SIZE OF NODULE 
SIZE OF 
LESION 
FOLLICULAR 
ADENOMA 
FOLLICULAR 
CARCINOMA 
1 to 2cm 30%   (n=10)    NIL 
2 to 4cm 60%   (n=20) 41%  (n=5) 
>4cm 10%    (n=3) 59%  (n=7) 
 
CHART - 5.   SAMPLES BASED ON SIZE OF NODULE 
 
 In this study 7 out of  12  cases ( 59 % )of  follicular carcinoma, 3 out of 33 
cases (10% ) of follicular adenoma  had  the size of  the  nodule   more than 4 cm. 
Kuru et al. (69) found that nodule size ≥4 cm was associated with increased risk of 
malignancy compared with nodule size <4 cm.  Kim et al. (125) performed a 
0%
10%
20%
30%
40%
50%
60%
70%
1to 2 cm
2 to 4cm
>4cm
30%
60%
10%
41%
59%
Follicular adenoma Follicular carcinoma
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retrospective study of 263 patients, who underwent thyroidectomy for nodules ≥4 
cm. A significant proportion of the nodules (58.6%) were malignant on final 
histopathology. 
TABLE -8; DISTRIBUTION OF FOLLICULAR THYROID CARCINOMA CASES 
BASED ON CAPSULAR AND VASCULAR INVASION 
INVASION  IN 
HISTOPATHOLOGY 
NO.OF FOLLICULAR 
THYROID 
CARCINOMA CASES 
PERCENTAGE 
VASCULAR INVASION 
ONLY 
n=2 17% 
CAPSULAR INVASION 
ONLY 
n=5 41% 
BOTH n=5 42% 
   
 
CHART 6.  DISTRIBUTION OF FOLLICULAR THYROID CARCINOMA CASES 
BASED ON CAPSULAR AND VASCULAR INVASION 
 
 
  
17%
41%
42%
FOLLICULAR  CARCINOMA
VASCULAR INVASION ONLY CAPSULAR INVASION ONLY BOTH
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RESULTS  OF  IMMUNOHISTOCHEMISTRY 
TABLE 9.  EXPRESSION  OF  CD56 AND GALECTIN 3 IN BENIGN AND 
MALIGNANT   FOLLICULAR TUMORS OF THYROID 
  CD56     EXPRESSION GAL3 EXPRESSION 
CASES NO. PERCENTAGE NO. PERCETAGE 
FOLLICULAR 
ADENOMA 
32 96.60% 1 3.03% 
FOLLICULAR 
CARCINOMA 
2 16.60% 10 83.30% 
 
 In  this  study  CD56 expression was  higher  in follicular adenoma ( 96.6% 
) and CD56 expression in follicular thyroid carcinoma was only 16.6%. 
GALECTIN 3 expression was higher in follicular thyroid  carcinoma (83.3%) and 
its expression in follicular adenoma was only 3.03%. 
TABLE-10.  IMMUNOHISTOCHEMICAL SCORING OF CD 56  AND  GALECTIN 3  
EXPRESSION  IN   FOLLICULAR  ADENOMA   OF THYROID 
MARKERS IMMUNOHISTOCHEMICAL SCORING  IN  FOLLICULAR  
ADENOMA 
 
0        1+    2+        3+ 
CD56   n=2 n=15     n=15 
GALECTIN 3     n=1   
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CHART 7 
 
                  In follicular adenoma  out of  33 cases , 2 cases showed 1+ ,15 cases 
showed 2+, and 15  cases showed 3+ positivity for CD56. Only 1 case showed 1+ 
positivity for  GALECTIN 3. 
 
A case of follicular adenoma showing CD 56 (3+)Membranous positivity(40x) 
n=2
n=15 n=15
n=1
0
2
4
6
8
10
12
14
16
0 1+ 2+ 3+
CD56  AND  GALECTIN 3  EXPRESSION  IN 
FOLLICULAR  ADENOMA
CD56
GALECTIN 3
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TABLE-11.  IMMUNOHISTOCHEMICAL SCORING OF CD56 AND GALECTIN 3 
EXPRESSION IN FOLLICULAR CARCINOMA OF THYROID 
  
 
 
CHART 8 
 
                   
  
n=3
n=5
n=2n=2
0
1
2
3
4
5
6
0 1+ 2+ 3+
CD56 AND GAL 3  EXPRESSION IN FOLLICULAR  
CARCINOMA
 GALECTIN 3
CD56
MARKERS 
IMMUNOHISTOCHEMICAL SCORING IN 
FOLLICUALR THYROID CARCINOMA 
 
0 1+ 2+ 3+ 
CD56 (n=2) 
  
n=2 
 GALECTIN 3(n=10) 
 
n=3 n=5 n= 2 
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CD56  EXPRESSION  IN  FOLLICULAR THYROID CARCINOMA 
 
IMMUNOHISTOCHEMICAL 
SCORING OF CD56 
 
0 1+ 2+ 3+ 
MINIMALLY INVASIVE 
FOLLICULAR CARCINOMA 
  
n=1 
 HURTHLE CELL 
CARCINOMA 
  
n=1 
  
GALECTIN 3 EXPRESSION IN FOLLICULAR THYROID CARCINOMA 
 
IMMUNOHISTOCHEMICAL     
SCORING OF GALECTIN 3 
 
0 1+ 2+ 3+ 
MINIMALLY INVASIVE 
FOLLICULAR CARCINOMA  
 
n=3 n=3 n=1 
WIDELY INVASIVE 
FOLLICULAR CARCINOMA 
  
n=2 n=1 
                      
 In  Follicular Thyroid  Carcinoma  out of  12 cases, 3 cases (Minimally 
invasive follicular carcinoma)  showed 1+, 5 cases (3 Minimally invasive 
follicular carcinoma ,2 Widely invasive follicular carcinoma)  showed 2+, and  2  
cases (1  Minimally invasive follicular carcinoma , 1 Widely invasive follicular 
carcinoma ) showed 3+ positivity for GALECTIN 3. Only 2cases  of (1  
Minimally invasive follicular carcinoma,1 Hurthle cell carcinoma) showed  2+  
positivity  for  CD 56.     
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A case of follicular carcinoma with capsular invasion shows GALECTIN 3 
(3+)-Cytoplasmic positivity(40x) 
Statistical Analysis: 
 Statistical  analysis  was  done  using  SSPS 11 software  . PEARSON Chi-
square test   with  2x2 contingency table was used to calculate p-value to ascertain 
statistical significance. Probability (p) values less than 0.05 were considered  
statistically significant.  
TABLE 12 
FOR BENIGN TUMORS CD56 GALECTIN 3 
SENSITIVITY 97% 3% 
SPECIFICITY 83% 17% 
POSITIVE PREDICTIVE VALUE 94% 9% 
NEGATIVE PREDICTIVE VALUE 91% 6% 
POSITIVE LIKELIHOOD RATIO 5.70 0.036 
NEGATIVE  LIKELIHOOD RATIO 0.036 5.70 
95% CONFIDENCE INTERVAL 13.09 – 1955.68 0.005-0.076 
ODDS RATIO 160 0.006 
 p VALUE <0.0001 <0.0001 
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TABLE 13 
FOR  MALIGNANT TUMORS CD56 GALECTIN 3 
SENSITIVITY 17% 83 % 
SPECIFICITY 3% 97% 
POSITIVE PREDICTIVE VALUE 6% 91% 
NEGATIVE PREDICTIVE VALUE 9% 94% 
POSITIVE LIKELIHOOD RATIO 0.175 27.6 
NEGATIVE  LIKELIHOOD RATIO 27.6 0.175 
95% CONFIDENCE INTERVAL 0.005-0.076 13.09 – 1955.68 
ODDS RATIO 0.006 160 
p VALUE <0.0001 <0.0001 
 
 With objective to compare markers Receiver Operating Curve(ROC)  was 
constructed .  
 Receiver operating characteristic curve (ROC) was generated by placing 
sensitivity (true positive fraction or rate) on the y axis and 100-specificity (false 
positive rate or fraction) on the x axis, and drawing a curve along the dots using 
online software (http://www.MEDCALC). Each point on the ROC plot represents 
a sensitivity/specificity pair corresponding to a particular cutoff. Quantitative 
measures of accuracy, for example,the Area Under the ROC curve (AUC) was 
also calculated by the software. The sensitivity, specificity, PPV, NPV, and 
corresponding 95% confidence interval  and odds ratio were calculated using 
online software (http://vassarstats.net/index.htm). 
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RECEIVER  OPERATING  CURVE (ROC) FOR  CD56  AND  GALECTIN 
3 EXPRESSION IN MALIGNANCY 
CHART 9 
 
 Area under the ROC curve (AUC)  
Area under the ROC curve (AUC)  0.936 
Standard Errora 0.0365 
95% Confidence intervalb 0.820 to 0.987 
z statistic 11.944 
Significance level P (Area=0.5) <0.0001 
 DeLong et al., 1988 a 
 Binomial exact b 
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CHART 10  
 
 Area under the ROC curve (AUC)  
Area under the ROC curve (AUC)  0.861 
Standard Errora 0.0670 
95% Confidence intervalb 0.725 to 0.946 
z statistic 5.388 
Significance level P (Area=0.5) <0.0001 
DeLong et al., 1988 a 
 Binomial exact b 
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Variable AUC SEa 95% CIb 
CD56 0.936 0.0365 0.820 to 0.987 
GALECTIN_3 0.861 0.0670 0.725 to 0.946 
 a DeLong et al., 1988 
 b Binomial exact 
 
 Receiver operating curve (ROC) for individual marker and combination of 
markers were obtained. Estimated binormal ROC curves, with lower and upper 
bounds of the asymmetric 95% confidence interval for true-positive fraction at a 
variety of false-positive fraction were demonstrated. 
 Area Unrder Curve (AUC) is used as a quantitative measure of accuracy 
for each marker. AUC<0.75 was not clinically useful and AUC=1 is perfect.(126)     
Inthis study Area Under Curve  for CD56 as a negative marker  was 0.936   with 
95 %  confidence interval(0.820 to0.987) and odds ratio  was 160. So  AUC  for 
CD56( as a negative marker)  found  to be  a good parameter in  detecting  
malignancies with a p value of< 0.0001. 
 Area Under Curve  for Galectin 3 marker  was 0.861  with 95 %  
confidence interval(0.725 to0.946) and odds ratio is160. So  AUC  for galectin 3 
found to be a good parameter in  detecting  malignancies with a p value of< 
0.0001.        
 
 In this study  CD56  showed  high sensitivity for follicular adenoma  of 
thyroid (97%)and  Galectin 3 showed high sensitivity for follicular carcinoma of 
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thyroid (83%).As a negative marker CD56  showed high specificity for follicular 
thyroid carcinoma(97%) . 
        When we combined two markers CD56 and GALECTIN 3 ,  specificity 
increased for malignancy. 
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6. ANNEXURE-I  ;  COLOR  PLATES 
FOLLICULAR  ADENOMA 
 
Figure 1:  Follicular adenoma of thyroid H &E stain ( under 40x) 
 
Figure 2: CD56 expression Follicular adenoma of thyroid shows 3+ 
membraneous positivity  ( under 10x) 
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Figure 3:CD56  expression in Follicular adenoma of thyroid  shows membranous 
positivity (3+) under  (40x) 
 
 
 
Figure 4: GALECTIN 3 shows negative expression in Follicular adenoma of 
thyroid under 10x 
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HYALINISING  TRABECULAR  ADENOMA 
 
Figure 5: Hyalinising Trabecular Adenoma  H&E Stain under(x10) 
 
 
 
Figure 6:  Hyalinising Trabecular Adenoma shows CD56 membranous positivity 
(3+) under( x40) 
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Figure 7:Hyalinising Trabecular Adenoma shows  Galectin - 3 Negativity   
under( 40x) 
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FOLLICULAR THYROID CARCINOMA 
 
 
Figure 8: Follicular Thyroid Carcinoma  with  angioinvasion , H&E stain under 
( 40x) 
 
Figure 9: CD56 shows negative expression in Follicular Carcinoma of 
Thyroid,under( 10x) 
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Figure 10: GALECTIN 3  expression  in  Follicular Thyroid Carcinoma shows 
cytoplasmic positivity( 3+) under 10x 
 
 
Figure 11 : GALECTIN 3  expression  in  Follicular Thyroid Carcinoma shows 
cytoplasmic positivity( 3+) under (40x) 
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HURTHLE CELL CARCINOMA 
 
 
Figure 12 :  HURTHLE CELL CARCINOMA H&E STAIN UNDER     ( 10x) 
 
 
 
Figure 13 : HURTHLE CELL CARCINOMA H&E STAIN UNDER ( 40 x) 
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Figure 14: CD 56 expression  in  Hurthle  Cell  Carcinoma  of thyroid  - 
Shows membranous positivity ( 2+)   under (40x) 
 
 
 
 
Figure 15 :  Galectin 3  shows negative expression  in  Hurthle cell carcinoma 
under (40x) 
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7. DISCUSSION 
 Thyroid tumors represent a wide spectrum  of tumors with different 
biological  behaviours. The majority of the tumors can be easily  diagnosed by 
distinctive  histopathological   features, but the separation  between follicular 
thyroid  adenoma and follicular thyroid  carcinoma (particularly minimally 
invasive type) is very difficult. The difference between follicular adenoma of 
thyroid and minimally invasive  follicular carcinoma  of thyroid warrants 
histological demonstration of full thickness capsular permeation and/or vessel  
invasion by the tumor thrombus .  The important  finding which distinguishes 
benign tumor  from malignant follicular  thyroid tumor is the presence or absence 
of unequivocal  capsular and/or vascular invasion .But  identification  of this 
finding  is very challenging due to incomplete capsular penetration, or due to  
some technical difficulties. For these reasons  investigators have focused on 
finding IHC markers that are differentially expressed in benign versus malignant 
follicular tumors. 
 In this  study   we  analysed  the expression of CD56 and GALECTIN 3 
between  follicular adenoma and follicular carcinoma of thyroid  
 CD56 is a neural adhesion molecule (NCAM) which  is  an antigen related 
to the follicular epithelial differentiation. Many previous studies revealed CD56 
expression was high  in  normal thyroid follicular cells  and benign follicular 
lesions as follicular adenomas and nodular hyperplasias .Reduced or loss of  
expression of  CD56 is interrelated with tumor progression of patients. In the  
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cases of papillary thyroid carcinoma, follicular  thyroid carcinoma and anaplastic  
thyroid carcinoma expression  of CD56 is reduced,or totally lost.  
CD56 EXPRESSION IN PREVIOUS STUDIES 
 Shin et al.  reported  that 100%  of  Follicular adenoma and 58.3% of 
Hurthle cell adenoma cases showed immunopositivity for CD56.(127)  Park et al. 
(128) found that  93.3% of Follicular adenoma (FA) and 90.5% of Hurthle cell 
adenoma( HN) cases cases were positive for CD56.  
 Abd El Atti and Shash (129) reported that  91.7% of Follicular adenoma (FA 
and 87.5% of cases of Hurthle cell adenoma (HN) and cases showed CD56 
expression. The studies of both El Demellawy (130) et al.  and(131)et al.  mentioned 
that  expression of CD56  was found  100% in  the studied cases of  Hurthle cell 
adenoma (HN) and  Follicular adenoma. 
 Using CD56 as a negative marker, the sensitivity and the specificity of 
CD56 were very impressive  in distinguishing  Follicular  Thyroid Carcinoma 
from Follicular adenoma and also in distinguishing  papillary carcinoma -
Follicular Variant (FVPC) from Follicular adenoma of thyroid(FA). Conversely, 
Dina et al agreed with the results, that the highest specificity  was attained in 
differentiating Follicular Thyroid Carcinoma( FTC ) from Follicular Tumor with 
Undetermined Malignant Potential( FT-UMP)  (130)  
CD56 EXPRESSION IN PRESENT STUDY 
 In agreement with those studies, this study  reported a high positive  
expression of CD56 in follicular adenoma cases compared to follicular thyroid  
carcinoma cases.  
 
 
82 
 
 In this  present study  CD56 showed  positive  membranous  expression  in  
(96.6%  )32 out of 33 benign (n=31 , follicular adenoma  and  n=1,  HTA) cases 
with  sensitivity of 97% and specificity of 83% , with Positive Predictive Value 
(PPV) 94% and Negative Predictive Value( NPV)  91%  in diagnosing benign 
tumors. CD56 expression is  only 16.6% (n=2 out of 12)   in Follicular Thyroid 
Carcinoma (FTC) cases. But  CD56 distinguished  Follicular Adenoma (FA) from  
Follicular Thyroid Carcinoma (FTC) with significant difference (p value is < 
0.0001). 
        CD56  expression is    absent  in  83.3% (10 out of 12)   of Follicular 
Thyroid Carcinoma cases with sensitivity of 83% and specificity of 97%, with 
Positive  and Negative Predictive Values (PPV and NPV) are  91% and 94%  
respectively in diagnosing malignant  tumors and its  p value is less than 0.0001. 
 The results of our study showed that    CD56 had lost  its expression   or 
expressed  less in  malignant  tumors than benign tumors.  In follicular  thyroid 
carcinoma the specificity of CD56 (as a negative marker) was highly remarkable 
in distinguishing benign from malignant thyroid  tumors(Follicular adenoma from  
Follicular  Carcinoma). 
 Variation among studies in respect to sensitivity and specificity of 
CD56was substantial (96,128,129) Sensitivity for carcinoma varied from 58 to 100 % 
with a median value of 84 % (recalculated average value for all studies is 80 %). 
Specificity values ranged from 46 to 100 %, with a median value of 92 %. 
 Galectin-3 is a [beta]-galactoside-binding lectin  with a molecular weight 
of 31 KD  which plays a significant role in a number of biologic processes. It has 
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a role in regulating cell-cell and cell-matrix interaction, adhesion, migration, and 
damaged cell repair. It has a role in inflammation and neoplastic transformation. 
This marker has been implicated in regulation of normal cellular proliferation 
,apoptosis, malignant transformation, and the metastasis of cancer cells. 
GALECTIN 3 EXPRESSION IN PREVIOUS  STUDIES 
 Many researchers  have found that galectin-3 is useful in discriminating 
benign from malignant thyroid lesions.(132,133)                      
 Saleh et al (89)have noticed  the results recording that galectin-3 showed 
85% sensitivity for  immunohistochemical  separation  between carcinomas and 
benign nodules (positive in 27.5 % of benign vs. 85.1% of malignant nodules). 
However, the specificity was only 72.4%. They also observed that  benign  
follicular lesions (both neoplastic and nonneoplastic) showed  lower expression 
than malignant tumors. 
 Kovacs et al  found  that cytoplasmic  expression of  Galectin-3 is an  
useful marker in the differential diagnosis of solitary encapsulated follicular 
thyroid  tumors, especially the minimally invasive follicular carcinoma of thyroid 
(134). Galectin-3 can aid in distinguishing minimally invasive follicular carcinoma 
from  follicular adenoma.  
 Gasbarri et al. (103) in his study observed that galectin-3 is never expressed 
in benign thyroid lesions. 
 Saggiorato et al. (86) observed only 4 out of 52 cases of follicular adenoma 
cases showing Galectin -3 immunopositivity. Whereas investigators analyzed that 
Galectin 3 was positive in  all other thyroid cancers  . 
 
 
84 
 
 In the same way, Orlandi et al(135) reported  that,even though all the thyroid 
cancers that they analyzed were Galectin -3immunopositive, only 3/29 FA 
exhibited such positivity.Some authors considered true Galectin -3-positive 
Follicular adenoma as an indication of potentially early or incipient carcinoma, in 
which the capsular and/or vascular invasion not  been observed yet histologically. 
(134) 
 In fact,it is possible that Galectin-3 nuclear localization is related only to 
cellular proliferation, whereas its cytoplasmic accumulation would represent the a 
sign of malignant cell transformation. This observation showed agreement with 
other studies .(136) 
 In this background, the presence of  Galectin- 3 positive  follicular 
adenomas should be considered as an a marker of malignant transformation. As 
this lectin is early expressed during the process of  malignant transformation, it 
could play a main role in cell growth, cell cycle, and antiapoptotic mechanisms 
(86). Some authors reported Galectin-3 as a very sensitive marker of follicular 
malignancy (137). Beesley et al. found this  lectin expression  in all follicular  
thyroid  carcinomas , in 1 out of 20 adenomas, and in three out of eight nodular 
goiters. (6)  
 Aratake et al. found galectin-3  expression in  five out of six follicular  
thyroid carcinomas and  in two out of 14 follicular  adenomas (138). Similarly, 
Nascimento et al. reported  galectin-3 positivity in 11 out of 14 carcinomas and 1 
out of 9  adenomas (139).  
 The reason for the contradictory results was explained by Park et al (140) 
who explained the discrepancies in the frequency of galectin-3 immunoreactivity 
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in benign lesions  .He stated that this controversy may be due  to the different 
antibody detection systems and the cutoff values for positive and negative 
staining.  
 In addition, Herrmann et al have found that galectin-3 was also expressed 
focally in reactive follicular epithelial cells  and in entrapped follicles in chronic 
lymphocytic thyroiditis. If a biotin-detection system  used in galectin 3 
immunostaining, variety of thyroid  lesions might  show  prominent  endogenous 
biotin like activity, which could cause bias in interpretation(93)Finally, they 
concluded that for  galectin-3 immunostaining, biotin-free detection systems could  
be useful.  Galectin -3 was  also expressed in places where the follicular cells 
were in large number in  a highly inflamed area and  both in cells without 
cytological atypia or with hurthle-cell transformation. The most likely explanation 
for the galectin-3 expression of  non-neoplastic follicular cells in an inflamed area 
may be due to the cytokines secreted by inflammatory cells .(28)  
  According to this explanation,  making the distinction between follicular 
adenomas and carcinomas based on galectin 3 positivity only  may be very 
dangerous. So the combination of galectin 3 with other markers increases the 
sensitivity and specificity in deciding whether the lesion is benign or malignant.  
    The best combination of immunohistochemical  markers for detecting 
malignancy were CD56 with Galectin 3 and Cytokeratin -19 with Galectin-3 
respectively. In accordance with the previous studies ,CD56 and Galectin -3 was  
the best  combination in  distinguishing   follicular carcinoma  from follicular 
adenoma of thyroid. 
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GALECTIN 3 EXPRESSION IN PRESENT STUDY 
 In  present  study galectin 3  showed  positive cytoplasmic expression in  
83.3 %(10 out of 12) FTC cases  and in  FA  its expression is only 3.03% (1 out of 
33) cases with  sensitivity of 83% and specificity of 97%, with PPV and NPV are  
91% and 94%  respectively in diagnosing malignant  tumors. CD56 expression is  
only 16.6% (n=2 out of 12)   in FTC (n=1 MIFC ,n=1 HCC) cases. Galectin 3  
distinguished   follicular adenoma from  follicular carcinoma  with  significant 
difference( p value is < 0.0001).  Hence  in our study Galectin 3 expression is 
higher in malignant (FTC) tumors than in benign( FA)tumors. 
 The results  in  this study  clearly explained  the  cytoplasmic expression of 
Galectin-3  made  significant difference between follicular thyroid  adenoma and 
follicular carcinoma minimally invasive type. 
           In this study galectin-3 was specifically expressed by malignant  thyroid 
tumors, showing that this molecule could be used as an adequate marker for 
malignant thyroid  follicular cells. 
 In  diagnosing  follicular  thyroid carcinoma,the  sensitive marker in our 
study  was Galectin 3, and the specific marker was CD56. When we combined 
two markers, we did not reach 100%specificity for malignancy, on the other hand 
values were increased  when compared to expression of single marker.  
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8. SUMMARY 
      This study was conducted in the Department Of Pathology, Tirunelveli 
Medical College .The slides were prepared from the cases that were diagnosed as 
follicular adenoma and follicular carcinoma of thyroid.  Totally out of 45 cases, 
33 cases were benign (follicular adenoma)and 12 were malignant (follicular 
thyroid caarcinoma). Immunohistochemistry   was  performed  using the markers 
CD56 and GALECTIN 3 for all  the 45 cases (follicular adenoma and follicular 
carcinoma). Among them CD56 showed positive expression for 32 out of 33 cases 
of follicular adenoma and 2 out of 12 cases of follicular  thyroid carcinoma 
.GALECTIN -3 showed positive expression for 10 out of 12 cases of Follicular 
Thyroid Carcinoma ,and 1 out of 33 cases of  follicular adenoma.  
 In this study, high rates (96.6%) of diffuse, strong, positive staining for 
CD56  were observed in  follicular adenoma,  whereas there were high rates 
(83.3%) of CD56 negativity in follicular thyroid carcinoma. Consistent with this, 
CD56 was found to be the more specific marker for follicular thyroid carcinoma. 
Galectin-3 is also a  reliable  sensitive marker in distinguishing follicular 
adenomas  from follicular thyroid  carcinomas. 
 Furthermore, the present study demonstrated that when a positive 
marker(Galectin -3) was added to the (CD56 )negative marker, the sensitivity and 
specificity of the two markers  CD56 and galectin-3, were increased (83% and 
97%,). Hence  in the differentiation of  benign  from  malignant follicular thyroid 
tumors  a panel of combination   of   two markers(CD56 and Galectin -3) achieved 
a more statistical significant difference  with  a p value of  less than 0.0001. 
               In this study ,the marker showing  higher sensitivity   for  follicular 
carcinoma of thyroid  was GALECTIN- 3 (83%) and the marker with higher 
specificity  was CD56 (97%) . 
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9. CONCLUSION 
We conclude   the following 
1. GALECTIN -3 is a sensitive marker for Follicular Thyroid 
Carcinoma(FTC). (83%). 
2. Loss of  expression of  CD56  is  found to be  very  specific  for Follicular 
Thyroid Carcinoma  (97%). 
3. A combination  of   the two markers CD56 and galectin 3 is found more  
specific for Follicular Carcinoma  of  Thyroid  . 
4. Immunoexpression of  CD 56 and GALECTIN 3  are hence postulated to 
be important  ancillary tests in the diagnosis of  follicular thyroid  
neoplasms, albeit it does not replace the conventional histopathological 
examination. 
5. Therefore, we conclude that a combination panel of CD56 and GALECTIN 
3  is an useful tool to increase the chance of detecting Follicular Thyroid 
Carcinoma. 
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